Apellis Pharmaceuticals Inc Earnings

Apellis Pharmaceuticals Inc’s revenue fell -10.61% since last year same period to $178.49Mn in the Q2 2025. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated 7.01% jump in its revenue since last 3-months.

Apellis Pharmaceuticals Inc’s net profit fell -11.93% since last year same period to $-42.15Mn in the Q2 2025. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated 54.3% jump in its net profits since last 3-months.

Apellis Pharmaceuticals Inc’s net profit margin fell -25.22% since last year same period to -23.61% in the Q2 2025. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated 57.29% jump in its net profit margins since last 3-months.

Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at 1.6 - a 433.33% jump from last quarter’s estimates.

Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at 1.6.

Apellis Pharmaceuticals Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Apellis Pharmaceuticals Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.